In the context of current demographics, with the percentage of the population age 60+ increasing and set to reach 2 billion people by 2050, the concept of drug drug interactions has become a hot topic. The increase in life expectancy comes with some challenges, as for example polymedication for chronic diseases. With up to 40% of over 65 year olds currently taking more than 4 prescription drugs, the risks of drug drug interactions are a cause for concern.
31/10/2016 | Tags:
Virtual screening (VS) is time and resource consuming. However, VS is nowadays usually preferred by experts over classic iterative molecular design, i.e. design, synthesis, and testing. How could computer-aided drug discovery (CADD) merge the two paradigms? The answer is Active Learning.Read More
15/09/2015 | Tags:
Last week Intelligent Pharma was invited to visit ALBA, the synchrotron of Barcelona. We attended to a workshop about industrial applications of synchrotron light for pharmaceutical companies and we spend almost the full day there: not only attending to the talks, but also visiting the facilities.
11/05/2015 | Tags:
A few days ago I read an article written by Scott J. Lusher, with whom we collaborated at Intelligent Pharma some years ago. The article is entitled “Data-driven medicinal chemistry in the era of big data” and it has been published in Drug Discovery Today.
The author says that modern research is characterised by four points:
i. The access to, and requirement to, manage large amounts of data.
ii. The requirement for all researchers to become data scientists.
iii. The increased complexity of research projects.
iv. The need to work effectively in larger teams with colleagues from multiple disciplines and multiple locations.Read More
28/10/2014 | Tags:
2 of 10